Cargando…

Diagnostic value of HSP90α and related markers in lung cancer

PURPOSE: To investigate the expression of heat shock protein 90α (HSP90α) in patients with lung cancer (LC) and the clinical value of HSP90α and other related markers in the diagnosis of LC. METHODS: Of 335 patients enrolled in the study cohort, 175 were screened for LC and 160 were healthy (HC). Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Zhimin, Wang, Longhao, Hong, Songlin, Shi, Changbei, Yuan, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169185/
https://www.ncbi.nlm.nih.gov/pubmed/35522136
http://dx.doi.org/10.1002/jcla.24462
_version_ 1784721154342125568
author Yuan, Zhimin
Wang, Longhao
Hong, Songlin
Shi, Changbei
Yuan, Bin
author_facet Yuan, Zhimin
Wang, Longhao
Hong, Songlin
Shi, Changbei
Yuan, Bin
author_sort Yuan, Zhimin
collection PubMed
description PURPOSE: To investigate the expression of heat shock protein 90α (HSP90α) in patients with lung cancer (LC) and the clinical value of HSP90α and other related markers in the diagnosis of LC. METHODS: Of 335 patients enrolled in the study cohort, 175 were screened for LC and 160 were healthy (HC). The plasma levels of HSP90α and related markers (CEA, NSE, CYFRA21‐1 and ProGRP) were detected in all individuals in the cohort by enzyme‐linked immunosorbent assay (ELISA). Groups were divided according to gender (male/female), age (≤60 years/>60 years), types of LC (small‐cell carcinoma, squamous carcinoma and adenocarcinoma), staging (I, II, III and IV) and metastasis (metastasis and non‐metastasis) separately. Wilcoxon Mann–Whitney test and Kruskal–Wallis test were used to compare statistical differences between two groups/among the multiple groups for each factor of HSP90α. The r‐value and Kappa were used to compare HSP90α with related markers, and the receiver operating curve (ROC) was used to evaluate the efficacy of plasma HSP90α in predicting LC. RESULTS: No statistical difference was found in the plasma level of HSP90α among different age and gender groups (p > 0.05). In the group divided by LC type, staging and metastasis status, there were statistical differences among different groups in HSP90α level (p < 0.05). The levels of HSP90α, CEA, NSE, CYFRA21‐1 and ProGRP in LC groups were significantly higher than HC (p < 0.001). R values of HSP90α correlated with other related markers in the diagnosis of LC (p < 0.05). Although HSP90α and other related markers did not fit the satisfactory conformance, in terms of the positive rate of diagnosis, it was statistically differences in the diagnostic positive rate between HSP90α and each marker (p < 0.01). ROC analysis showed that a plasma HSP90α cut‐off point of 50.02 ng/ml had an optimal predictive value for LC. CONCLUSIONS: HSP90α has significant clinical value in early screening and diagnosis of LC. The combined application of HSP90α and related markers can improve the positive rate of early diagnosis of LC effectively.
format Online
Article
Text
id pubmed-9169185
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-91691852022-06-07 Diagnostic value of HSP90α and related markers in lung cancer Yuan, Zhimin Wang, Longhao Hong, Songlin Shi, Changbei Yuan, Bin J Clin Lab Anal Research Articles PURPOSE: To investigate the expression of heat shock protein 90α (HSP90α) in patients with lung cancer (LC) and the clinical value of HSP90α and other related markers in the diagnosis of LC. METHODS: Of 335 patients enrolled in the study cohort, 175 were screened for LC and 160 were healthy (HC). The plasma levels of HSP90α and related markers (CEA, NSE, CYFRA21‐1 and ProGRP) were detected in all individuals in the cohort by enzyme‐linked immunosorbent assay (ELISA). Groups were divided according to gender (male/female), age (≤60 years/>60 years), types of LC (small‐cell carcinoma, squamous carcinoma and adenocarcinoma), staging (I, II, III and IV) and metastasis (metastasis and non‐metastasis) separately. Wilcoxon Mann–Whitney test and Kruskal–Wallis test were used to compare statistical differences between two groups/among the multiple groups for each factor of HSP90α. The r‐value and Kappa were used to compare HSP90α with related markers, and the receiver operating curve (ROC) was used to evaluate the efficacy of plasma HSP90α in predicting LC. RESULTS: No statistical difference was found in the plasma level of HSP90α among different age and gender groups (p > 0.05). In the group divided by LC type, staging and metastasis status, there were statistical differences among different groups in HSP90α level (p < 0.05). The levels of HSP90α, CEA, NSE, CYFRA21‐1 and ProGRP in LC groups were significantly higher than HC (p < 0.001). R values of HSP90α correlated with other related markers in the diagnosis of LC (p < 0.05). Although HSP90α and other related markers did not fit the satisfactory conformance, in terms of the positive rate of diagnosis, it was statistically differences in the diagnostic positive rate between HSP90α and each marker (p < 0.01). ROC analysis showed that a plasma HSP90α cut‐off point of 50.02 ng/ml had an optimal predictive value for LC. CONCLUSIONS: HSP90α has significant clinical value in early screening and diagnosis of LC. The combined application of HSP90α and related markers can improve the positive rate of early diagnosis of LC effectively. John Wiley and Sons Inc. 2022-05-06 /pmc/articles/PMC9169185/ /pubmed/35522136 http://dx.doi.org/10.1002/jcla.24462 Text en © 2022 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Yuan, Zhimin
Wang, Longhao
Hong, Songlin
Shi, Changbei
Yuan, Bin
Diagnostic value of HSP90α and related markers in lung cancer
title Diagnostic value of HSP90α and related markers in lung cancer
title_full Diagnostic value of HSP90α and related markers in lung cancer
title_fullStr Diagnostic value of HSP90α and related markers in lung cancer
title_full_unstemmed Diagnostic value of HSP90α and related markers in lung cancer
title_short Diagnostic value of HSP90α and related markers in lung cancer
title_sort diagnostic value of hsp90α and related markers in lung cancer
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169185/
https://www.ncbi.nlm.nih.gov/pubmed/35522136
http://dx.doi.org/10.1002/jcla.24462
work_keys_str_mv AT yuanzhimin diagnosticvalueofhsp90aandrelatedmarkersinlungcancer
AT wanglonghao diagnosticvalueofhsp90aandrelatedmarkersinlungcancer
AT hongsonglin diagnosticvalueofhsp90aandrelatedmarkersinlungcancer
AT shichangbei diagnosticvalueofhsp90aandrelatedmarkersinlungcancer
AT yuanbin diagnosticvalueofhsp90aandrelatedmarkersinlungcancer